Lobbying stalls generic **** legislation

WASHINGTON - Legislation aimed at speeding the availability of cheaper generic ***** has stalled in Congress in the face of major lobbying by the **** industry.

...A plaintiff in that case, Helen Donega of North Adams, Mass., said she was saving only about 5 percent off the brand-name price when she purchased the Barr generic tamoxifen in 1998 and 1999. Donega, who had insurance through Medicare but no **** coverage, said she had to pay between $85 and $90 a month for the ****.

She eventually bought tamoxifen in Canada for about one-10th of the price she was paying in the U.S.

Donega, 75, who had a mastectomy and has been cancer-free for several years, said she was amazed when she learned of the deal between Barr and AstraZeneca, which sold tamoxifen under the brand name Nolvadex. AstraZeneca's patent on the **** has since expired.

"I must have been naive. I thought the government was on our side," she said. "No, the government isn't on our side. Big PhRMA is powerful and has a lot of money. That's whose side they're on."


Premium Link Upgrade
 

Premium Content

This thread contains exclusive content for our premium community members.

What you're missing:
  • Full discussion and replies
  • Community interaction and voting
Already have an account?
✨ Unlock exclusive discussions and premium features
Premium Benefits:
Exclusive content • Priority support • Advanced features • Full thread access
Top